SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Exact Sciences Corporation (EXAS)

NEW YORK, May 15, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Exact Sciences Corporation ("Exact" or the "Company") (NASDAQ: EXAS). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/exas.

The investigation concerns whether Exact and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On May 15, 2017, Citron Research published a report on Exact and stated, "Exact Sciences pushes a cancer test (Cologuard) to the public, inferior by its own admission, and loses money doing it." Cologuard is a branded laboratory-based scan for DNA traces in stool samples, indicating colorectal cancer. Citron mentioned a recent account from United Healthcare, that disapproved of the use of fecal DNA testing for colorectal cancer screening and monitoring, and found it to be "unproven and not medically necessary." The Citron article stated that "key metrics not disclosed by Exact Sciences are getting worse, while Medicare pricing inefficiencies end next January and investors will be left with a decaying asset with no terminal value." The article continued to say that "Poop in a box will probably be a medical dinosaur in 4 years and the value of Exact's only asset will be 0."

If you are aware of any facts relating to this investigation, or purchased shares of Exact's, you can assist this investigation by visiting the firm's site: www.bgandg.com/exas. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC

Related Links

http://www.bgandg.com